Previous 10 | Next 10 |
A majority of an FDA advisory committee agreed that Avenue Therapeutics (NASDAQ:ATXI) had not submitted adequate information to support the position that the benefits of intravenous (“IV”) tramadol outweighed the risks. The company announced the outcome of the U.S...
NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced the outcome of the U.S. Food and Drug Administration (“...
NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced that NASDAQ has halted trading of the Company’s common...
The U.S. Food and Drug Administration (FDA) has released briefing documents on Friday ahead of an advisory committee meeting scheduled on Feb. 15 to discuss the New Drug Application submitted by Avenue Therapeutics (NASDAQ:ATXI) for approval of intravenous (“IV”) tramadol. The c...
A Crash Course In Penny Stock Basics If you’re looking for ways to make money in the stock market, penny stocks may be something that comes to mind first. They’re cheap, they’re known for providing handsome returns, and all the Apes seem to love them. A classic exam...
NEW YORK, NY / ACCESSWIRE / December 15, 2021 / Aegis Capital Corp. acted as Sole Bookrunner on a $2 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ:ATXI). About Avenue Therapeutics Avenue Therapeutics is a specialty pharmaceutical company whose mission is to de...
Gainers: Nuverra Environmental Solutions (NYSE:NES) +88%. Arena (NASDAQ:ARNA) +82%. BELLUS (NASDAQ:BLU) +56%. Foghorn Therapeutics (NASDAQ:FHTX) +43%. Petros Pharmaceuticals (NASDAQ:PTPI) +45%. Biofrontera (NASDAQ:BFRI) +29%. Mawson Infrastructure Group (OTCQB:MIGI) +17%. Reliance Global Grou...
Gainers: Arena Pharmaceuticals (NASDAQ:ARNA) +84%, BELLUS Health (NASDAQ:BLU) +68%, Foghorn Therapeutics (NASDAQ:FHTX) +37%, Petros Pharmaceuticals (NASDAQ:PTPI) +27%, Tabula Rasa HealthCare (NASDAQ:TRHC) +23%. Losers: IGM Biosciences (NASDAQ:IGMS)...
Avenue Therapeutics (NASDAQ:ATXI) -22% after pricing $2M stock offering. X4 Pharmaceuticals (NASDAQ:XFOR) -11% presents new clinical and scientific data at 2021 ASH annual meeting supporting broader potential for Mavorixafor in the treatment of primary Immunodeficiencies....
NEW YORK, Dec. 12, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced the pricing of an underwritten public offering with gross pro...
News, Short Squeeze, Breakout and More Instantly...
Avenue Therapeutics Inc. Company Name:
ATXI Stock Symbol:
NASDAQ Market:
Avenue Therapeutics Inc. Website:
MIAMI, June 20, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced tha...
MIAMI, May 16, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the ...
– Raised a total of $9.4 million in gross proceeds from warrant exercise transactions since January 2024 – MIAMI, May 15, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutica...